Eating higher amounts of protein could help people with colorectal cancer keep crucial muscle mass while undergoing ...

Agenus Inc. ("Agenus" or the "Company") (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024 ...

Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

Only half of people with early-onset cancers reported discussing fertility preservation options prior to their oncology ...

Researchers have discovered that semaglutide weight loss drugs like Ozempic may reduce the risk of early-onset colorectal cancer (CRC) in diabetes patients. Inspired by the troubling trend ...

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC ...

First patient dosed in Phase 1 clinical trial evaluating ZW171 in advanced mesothelin (MSLN)-expressing cancers Preclinical data presented on ...

I initially put off a colonoscopy due to gastroesophageal reflux disease, but after a positive home screening test, I underwent the procedure and was diagnosed with stage 3 rectal cancer. Carla ...

I’ve been worried by the reports of colorectal cancer rising among younger people. What can I do to lower my risk? Although we don’t have control over many aspects of why we develop cancer ...

Delcath Systems, Inc. (NASDAQ:DCTH) Q3 2024 Earnings Call ... medical oncologists at leading cancer centers with the ...

The colorectal study was designed to ... Also, since the release of ivonescimab data during September 2024 at World Conference on Lung Cancer and ESMO Annual Meeting, we have seen an increase ...